JP2023510965A - メトトレキサート投薬形態 - Google Patents

メトトレキサート投薬形態 Download PDF

Info

Publication number
JP2023510965A
JP2023510965A JP2022544104A JP2022544104A JP2023510965A JP 2023510965 A JP2023510965 A JP 2023510965A JP 2022544104 A JP2022544104 A JP 2022544104A JP 2022544104 A JP2022544104 A JP 2022544104A JP 2023510965 A JP2023510965 A JP 2023510965A
Authority
JP
Japan
Prior art keywords
minutes
methotrexate
pharmaceutical composition
release
pellets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022544104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510965A5 (https=
Inventor
ホイゴー，ベント
ダムゴー・ジェンセン，ハンネ
Original Assignee
ロス・セラピューティクス・エ・ピ・エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロス・セラピューティクス・エ・ピ・エス filed Critical ロス・セラピューティクス・エ・ピ・エス
Publication of JP2023510965A publication Critical patent/JP2023510965A/ja
Publication of JP2023510965A5 publication Critical patent/JP2023510965A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022544104A 2020-01-27 2021-01-26 メトトレキサート投薬形態 Pending JP2023510965A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20153818.8 2020-01-27
EP20153818.8A EP3854385A1 (en) 2020-01-27 2020-01-27 Methotrexate dosage form
PCT/DK2021/050025 WO2021151442A2 (en) 2020-01-27 2021-01-26 Methotrexate dosage form

Publications (2)

Publication Number Publication Date
JP2023510965A true JP2023510965A (ja) 2023-03-15
JP2023510965A5 JP2023510965A5 (https=) 2024-01-10

Family

ID=69326391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544104A Pending JP2023510965A (ja) 2020-01-27 2021-01-26 メトトレキサート投薬形態

Country Status (5)

Country Link
US (1) US20230051463A1 (https=)
EP (2) EP3854385A1 (https=)
JP (1) JP2023510965A (https=)
CA (1) CA3163555A1 (https=)
WO (1) WO2021151442A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
CN119235808A (zh) * 2024-11-21 2025-01-03 江苏知原药业股份有限公司 一种甲氨蝶呤包衣片及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027911A1 (fr) * 1997-12-03 1999-06-10 Fujisawa Pharmaceutical Co., Ltd. Medicament en pastilles souples et procede de fabrication
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
CN103417544A (zh) * 2012-05-22 2013-12-04 欣凯医药化工中间体（上海）有限公司 甲氨叶酸复方制剂及其制备方法和用途
JP2016510068A (ja) * 2013-03-08 2016-04-04 ノバルティス アーゲー デフェラシロクスの経口製剤
JP2017533274A (ja) * 2014-10-29 2017-11-09 セラカインド リミテッドＴｈｅｒａｋｉｎｄ Ｌｔｄ メトトレキサート製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2271560C (en) * 1996-11-15 2003-09-23 Mayo Foundation For Medical Education And Research Pharmaceutical dosage form for colonic delivery
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US8007827B2 (en) 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
WO2006122414A1 (en) * 2005-05-17 2006-11-23 Matregen Corp. Depot for sustained and controlled delivery of methotrexate
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2010065491A2 (en) * 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
CN107714653B (zh) * 2017-11-27 2022-01-28 济南新科医药科技有限公司 一种稳定的可溶性甲氨蝶呤颗粒剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027911A1 (fr) * 1997-12-03 1999-06-10 Fujisawa Pharmaceutical Co., Ltd. Medicament en pastilles souples et procede de fabrication
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
CN103417544A (zh) * 2012-05-22 2013-12-04 欣凯医药化工中间体（上海）有限公司 甲氨叶酸复方制剂及其制备方法和用途
JP2016510068A (ja) * 2013-03-08 2016-04-04 ノバルティス アーゲー デフェラシロクスの経口製剤
JP2017533274A (ja) * 2014-10-29 2017-11-09 セラカインド リミテッドＴｈｅｒａｋｉｎｄ Ｌｔｄ メトトレキサート製剤

Also Published As

Publication number Publication date
WO2021151442A2 (en) 2021-08-05
EP4096641A2 (en) 2022-12-07
EP3854385A1 (en) 2021-07-28
WO2021151442A3 (en) 2021-09-10
CA3163555A1 (en) 2021-08-05
US20230051463A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
TWI440480B (zh) 包含弱鹼性藥物及有機酸之藥物遞送系統
US20160220493A1 (en) Oral formulations of deferasirox
CN102458117A (zh) 含有非阿片样和阿片样止痛药的组合的口腔崩解片组合物
JP5671609B2 (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
HK1253735A1 (zh) 控制延缓释放普瑞巴林
US20060013875A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
CN1538837A (zh) 含有对乙酰氨基酚的吞咽片
JP2023510965A (ja) メトトレキサート投薬形態
TWI883162B (zh) 一種非布司他片
EP3331502B1 (en) Controlled release propiverine formulations
WO2009027786A2 (en) Matrix dosage forms of varenicline
EP3796908B1 (en) Controlled release propiverine formulations
WO2023089553A1 (en) Controlled release formulations of flavoxate and process for preparation thereof
JP6713483B2 (ja) ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形
US20080207593A1 (en) Antihistamine Combination
WO2018185669A1 (en) Effervescent compositions comprising saxagliptin or salt thereof
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
CN1942175B (zh) 24小时有效的曲马多缓释制剂
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
EP3251661A1 (en) Raloxifene sprinkle composition
JPWO2003075918A1 (ja) 塩酸ピルジカイニド含有錠剤（湿式）
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
CN108066347A (zh) 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
WO2007122474A2 (en) Extended release formulations
HK1212242B (en) Oral formulations of deferasirox

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260119